EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act): Epigenomics AG: Strategic Partner Abbott Launches Colorectal Cancer Blood Test in Europe and Asia/Pacific

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Licensing Agreements/Molecular diagnostics

21.12.2009

Berlin, December 21, 2009 - Epigenomics AG (ISIN: DE000A0BVT96), a
cancer molecular diagnostics company, informs that its strategic
licensing and collaboration partner Abbott launched a molecular
diagnostic blood test to aid in the diagnosis of colorectal cancer in
Europe and Asia/Pacific. The in vitro diagnostic test is based on
Epigenomics´ proprietary biomarker Septin9. Abbott licensed the
non-exclusive worldwide rights to Septin9 in September 2007. The in
vitro diagnostic test is commercialized by Abbott under the brand
name Abbott RealTime mS9 Colorectal Cancer Assay and is optimized for
Abbott´s RealTime system m2000. The launch triggers a milestone
payment to Epigenomics. Going forward Epigenomics will participate in
the commercial success of the mS9 Colorectal Cancer Assay through
royalties on product sales as well as certain sales-related
milestones. With the launch Epigenomics continues executing its dual
business model of non-exclusive licensing and direct
commercialization of its cancer molecular diagnostic tests.

End of Ad hoc

Epigenomics legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward- looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale in the
United States. The analytical and clinical performance
characteristics of any product based on this technology which may be
sold at some future time in the U.S. have not been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade